Crossject Société Anonyme (EPA:ALCJ)
France
· Delayed Price · Currency is EUR 2.175
-0.010 (-0.46%)
Dec 5, 2025, 5:35 PM CET
Crossject Société Anonyme Revenue
Crossject Société Anonyme had revenue of 1.54M EUR in the half year ending June 30, 2025, a decrease of -50.29%. This brings the company's revenue in the last twelve months to 4.07M, up 72.88% year-over-year. In the year 2024, Crossject Société Anonyme had annual revenue of 4.12M with 6.28% growth.
Revenue (ttm)
4.07M
Revenue Growth
+72.88%
P/S Ratio
28.16
Revenue / Employee
39.54K
Employees
102
Market Cap
114.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.12M | 243.00K | 6.28% |
| Dec 31, 2023 | 3.87M | -3.19M | -45.18% |
| Dec 31, 2022 | 7.06M | 583.00K | 9.00% |
| Dec 31, 2021 | 6.48M | 1.64M | 33.77% |
| Dec 31, 2020 | 4.84M | -58.27K | -1.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 27.24B |
| Sanofi | 45.93B |
| Sartorius Stedim Biotech | 2.95B |
| bioMérieux | 4.12B |
| Eurofins Scientific SE | 7.14B |
| Ipsen | 3.76B |
| ABIVAX Société Anonyme | 6.02M |
| Virbac | 1.43B |